Dexma
Monthly
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining the. Rated medium severity (CVSS 5.3), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps the session active, since the. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow an attacker with access to the network, where clients have access to the DexGate. Rated medium severity (CVSS 6.5), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload. Rated medium severity (CVSS 6.1), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to an exposure of sensitive information to an unauthorized actor vulnerability, which may allow an attacker to create malicious requests for obtaining the. Rated medium severity (CVSS 5.3), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to a cross-site request forgery vulnerability, which may allow an attacker to perform actions with the permissions of a victim user. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to an improper authentication vulnerability, which may allow an attacker to impersonate a legitimate user as long as the device keeps the session active, since the. Rated high severity (CVSS 8.8), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to a cleartext transmission of sensitive information vulnerability, which may allow an attacker with access to the network, where clients have access to the DexGate. Rated medium severity (CVSS 6.5), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.
The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload. Rated medium severity (CVSS 6.1), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.